ObjectiveTo explore the feasibility of laparoscopic hepatectomy of malignant liver tumors under the day surgery management model based on the concept of enhanced recovery after surgery (ERAS). MethodsThree patients who underwent laparoscopic resection of malignant liver tumors under day surgery model in the Department of Hepatobiliary Surgery of the First Affiliated Hospital of Guangxi Medical University from June to November 2022 were retrospectively collected. The clinical application effects of this model were comprehensively evaluated. ResultsAll 3 patients (cases 1–3) successfully completed complete laparoscopic partial liver resection, with operation time of 155, 183, and 201 min, respectively, as well as intraoperative blood loss of 20, 100, and 50 mL, respectively. Postoperative pathology confirmed that cases 1 and 2 were hepatocellular carcinoma, and case 3 was rectal adenocarcinoma with liver metastasis, and the resection margins all met the R0 standard. All patients resumed oral feeding at 6 h after surgery and were able to get out of bed at 8 h after surgery. All 3 patients were discharged within 24 h after surgery. The hospitalization cost of the three patients was (22 602.0±3 400.0) yuan. All patients were followed up for more than 24 months and maintained a tumor-free survival state, without tumor recurrence and metastasis. ConclusionThe results of this limited cases suggest that laparoscopic liver resection under day surgery model is initially feasible and safe for strictly selected patients with liver malignancies combined with a standardized ERAS management pathway.
ObjectiveTo exploring the technical feasibility and safety of transradial sheathless microcatheter- hepatic arterial infusion chemotherapy (TRSM-HAIC) for malignant liver tumors. MethodsThe clinical data of patients with malignant liver tumors who underwent TRSM-HAIC in the Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, from November 2025 to March 2026, were retrospectively collected. The recorded parameters included procedural core metrics (such as puncture success rate, technical success rate, total procedure time), perioperative complications (according to CIRSE classification), postoperative recovery outcomes (immobilization time, hospital stay), and radial artery patency. ResultsA total of 20 patients underwent 36 sessions of TRSM-HAIC. The 36 sessions of TRSM-HAIC performed on 20 patients were all completed successfully. Both the puncture success rate and the technical success rate reached 100%, with no case requiring conversion to an alternative access route. The total procedure time was (40.5±12.8) min, with a median of 38.0 min. The median time from puncture to successful microcatheter placement in the hepatic artery was 4.5 min. During the perioperative period, only one minor puncture site hematoma (CIRSE grade 1 complication) was observed. No complications such as severe hemorrhage, hematoma, vascular spasm, dissection, or thrombosis occurred. No strict immobilization was required postoperatively and the postprocedural hospital stay was (4.5±1.2) d, with a median of 4 d. All 12 patients who required repeat treatment chose to continue with this method, and no new vascular complications arose during subsequent sessions. All patients maintained radial artery patency after the procedure. ConclusionsTRSM-HAIC is a safe and feasible innovative interventional technique. Its advantages include a 100% technical success rate, a low complication rate, and rapid postoperative recovery, providing a new minimally invasive option for malignant liver tumors. This is particularly relevant for patients requiring multiple interventional therapies or those unable to tolerate prolonged immobilization. Its long-term vascular protective effect and oncological outcomes warrant further validation in larger cohorts with extended follow-up.